Skip to main content

Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site.

Publication ,  Journal Article
Hirshberg, B; Montgomery, S; Wysoki, MG; Xu, H; Tadaki, D; Lee, J; Hines, K; Gaglia, J; Patterson, N; Leconte, J; Hale, D; Chang, R; Kirk, AD ...
Published in: Diabetes
July 2002

We've established a nonhuman primate islet allotransplant model to address questions such as whether transplanting islets into the gut's arterial system would more safely and as effectively support long-term islet allograft survival compared with the traditional portal vein approach. We reasoned that islets make up <2% of pancreatic cell mass but consume an estimated 20% of arterial blood flow, suggesting an advantage for the arterial site. Access to the arterial system is also easier and safer than the portal system. Pancreatectomized rhesus macaques were transplanted with allogeneic islets infused into either the portal vein (n = 6) or the celiac artery (n = 4). To prevent rejection, primates were given daclizumab, tacrolimus, and rapamycin. In five of six portal vein experiments, animals achieved normoglycemia without exogenous insulin. In contrast, none of the animals given intra-arterial islets showed even transient insulin independence (P = 0.048). Two of the latter animals received a second islet transplant, this time to the portal system, and both achieved insulin independence. Thus, intraportal islet transplantation under conventional immunosuppression is feasible in primates and can result in long-term insulin independence when adequate immunosuppression is maintained. Arterial islet injection, however, does not appear to be a viable islet transplantation technique.

Duke Scholars

Published In

Diabetes

DOI

ISSN

0012-1797

Publication Date

July 2002

Volume

51

Issue

7

Start / End Page

2135 / 2140

Location

United States

Related Subject Headings

  • Transplantation, Homologous
  • Portal Vein
  • Organ Size
  • Macaca mulatta
  • Islets of Langerhans Transplantation
  • Islets of Langerhans
  • Graft Survival
  • Graft Rejection
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hirshberg, B., Montgomery, S., Wysoki, M. G., Xu, H., Tadaki, D., Lee, J., … Harlan, D. M. (2002). Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. Diabetes, 51(7), 2135–2140. https://doi.org/10.2337/diabetes.51.7.2135
Hirshberg, Boaz, Sean Montgomery, Michael G. Wysoki, He Xu, Doug Tadaki, Janet Lee, Kenneth Hines, et al. “Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site.Diabetes 51, no. 7 (July 2002): 2135–40. https://doi.org/10.2337/diabetes.51.7.2135.
Hirshberg, Boaz, et al. “Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site.Diabetes, vol. 51, no. 7, July 2002, pp. 2135–40. Pubmed, doi:10.2337/diabetes.51.7.2135.
Hirshberg B, Montgomery S, Wysoki MG, Xu H, Tadaki D, Lee J, Hines K, Gaglia J, Patterson N, Leconte J, Hale D, Chang R, Kirk AD, Harlan DM. Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site. Diabetes. 2002 Jul;51(7):2135–2140.

Published In

Diabetes

DOI

ISSN

0012-1797

Publication Date

July 2002

Volume

51

Issue

7

Start / End Page

2135 / 2140

Location

United States

Related Subject Headings

  • Transplantation, Homologous
  • Portal Vein
  • Organ Size
  • Macaca mulatta
  • Islets of Langerhans Transplantation
  • Islets of Langerhans
  • Graft Survival
  • Graft Rejection
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 1